Company profile
Rapid Dose Therapeutics Corp.
OTC: RDTCF · Healthcare · Biotechnology
Canadian filerHQ Burlington, ONReports USD
#798 of 1,418 Healthcare companies by revenue72nd-percentile growth
EA Score
38DFH 29DQ —GM 66SS 37
v0.1 · 45/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$1.9M
Rev growth YoY (TTM)
+5.8%
Net income (FY)
-$2.4M
Employees
12
as of 2026-08-22
Market cap
$11.5M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.0M2.8M CAD2026
Net income-$2.4M-3.4M CAD2026
Operating income-$1.2M-1.7M CAD2026
Total assets$2.4M3.3M CAD2026
Liabilities$7.7M10.5M CAD2026
Equity-$5.3M-7.2M CAD2026
Revenue trend
FY2019 – FY2026 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rapid Dose Therapeutics Corp.’s revenue?
Rapid Dose Therapeutics Corp. booked $2.0M in FY2026 revenue, growing 33% year over year — faster than most Healthcare companies we track, at a -122.2% net margin.
Peers · Healthcare
Cocrystal Pharma, Inc.31DSagimet Biosciences Inc.36DOramed Pharmaceuticals Inc.61CPressure BioSciences, Inc.——Lipocine Inc.48DTHC Biomed Intl Ltd.——Key facts
CEOMark Andrew Upsdell
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlington, ON
ExchangeOTC: RDTCF
Employees12
IPO date2019-09-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.